Highlights
- Third quarter 2026 YARTEMLEA product sales, net were $35,934 thousand, with no product sales in the prior-year quarter.
- Third quarter net loss was $57,356 thousand, or $0.79 per share, including a $62,020 thousand Fair Value loss on financial instruments.
- On October 16, 2026, the CHMP issued a negative opinion on the narsoplimab Marketing authorization application following re-examination.
- Cash, cash equivalents and short-term investments were $95.3 million, and Omeros expects to fund more than 12 months of operations.
Omeros Corporation (NASDAQ:OMER) shares were trading at USD 13.77 on November 17, 2026, down 17.45%, with a relative Volume at time of 9.19. The commercial-stage biotechnology company completed two repurchases of its 2029 convertible notes in July, announced a negative CHMP opinion on narsoplimab on October 16 and filed its Form 10-Q for the quarter ended September 30, 2026 on November 16.
Omeros is a Washington corporation with principal executive offices in Seattle, Washington. It describes itself as a commercial-stage biotechnology company that develops protein and small-molecule therapeutics for large-market and orphan indications. Its product YARTEMLEA (narsoplimab-wuug) is approved in the U.S. for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Its pipeline targets complement-mediated diseases, cancers, addictive or compulsive disorders and infectious diseases. Its fiscal year ends December 31, and 74,463,571 shares of common stock were outstanding as of November 11, 2026.
Third Quarter Results
For the quarter ended September 30, 2026, Omeros reported YARTEMLEA product sales, net of $35,934 thousand, and $74,356 thousand for the nine months. Gross product sales were $41,774 thousand.
Research and development expenses were $16,060 thousand, compared with $15,995 thousand, and selling, general, and administrative expenses were $14,547 thousand, compared with $10,397 thousand. Income from operations was $4,501 thousand, compared with a loss from operations of $26,392 thousand.
The net loss on change in fair value of financial instruments was $62,020 thousand, and the loss on early extinguishment of 2029 Notes was $1,905 thousand. Net Income from discontinued operations was $6,469 thousand. The net loss was $57,356 thousand, or $0.79 per share, compared with $30,917 thousand, or $0.47 per share. For the nine months, net income was $11,936 thousand, compared with a net loss of $89,801 thousand.
On the call, management said non-GAAP adjusted net income was $4.7 million, or $0.06 per share.
YARTEMLEA Launch and CHMP Opinion
The FDA approved YARTEMLEA on December 23, 2025, and commercial sales began in January 2026. By September 30, 2026, 109 unique accounts had ordered YARTEMLEA, which the company described as a 49% increase in ordering accounts since June 30, 2026.
On October 16, 2026, Omeros announced that the CHMP of the European Medicines Agency issued a negative opinion on its marketing authorization application for narsoplimab in TA-TMA following re-examination of a negative opinion adopted in June 2026. The company said it does not expect YARTEMLEA to be authorized in the European Union on the basis of the current application. It is exploring approvals in other countries and evaluating partnerships outside the U.S.
Balance Sheet, Debt and Capital
At September 30, 2026, cash and cash equivalents were $5,070 thousand and short-term investments were $90,180 thousand. Total Assets were $248,095 thousand and the total shareholders' Deficit was $89,973 thousand.
In July 2026, Omeros repurchased $30.5 million aggregate principal amount of its 2029 Notes for a total purchase price of $60.2 million, plus accrued interest, leaving approximately $40.3 million outstanding. For the nine months, it repurchased and retired 0.8 million shares at an average cost of $11.70 per share. The $150.0 million at-the-market program was unused.
Outlook and Pipeline
The company expects fourth quarter 2026 Research and Development expenses to be higher than in the third quarter, selling, general, and administrative expenses to be slightly higher, and interest expense to be comparable. On the call, management said it is not guiding to fourth quarter revenue. Studies of YARTEMLEA in acute respiratory distress syndrome and in preventing high-risk TA-TMA in pediatric patients are planned to begin later this year or early 2027. A first-in-human OncotoX-AML trial is targeted for late 2027. Omeros received $240.0 million upfront from Novo Nordisk for zaltenibart and is eligible for up to $510.0 million in development and approval milestones.






Please wait processing your request...